TriangleNCT03846427 · OUTCOME
Elimination Half Life (t1/2)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Hours
- Interval / dispersion
- Full Range
- Time frame
- Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)
Analysis population: Pharmacokinetic analysis set included all participants who had at least 1 postdose zanubrutinib plasma concentration
Groups in this outcome
Zanubrutinib
Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent
| Group | Source count |
|---|---|
| Zanubrutinib | 9 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Zanubrutinib | 1.2 | Not reported | 0.8 | 2.7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.8
- upper Limit
- 2.7
- value
- 1.2
- denoms
- counts
- group Id
- OG000
- value
- 9
- units
- Participants
- dispersion Type
- Full Range
- groups
- description
- Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent
- id
- OG000
- title
- Zanubrutinib
- param Type
- MEDIAN
- population Description
- Pharmacokinetic analysis set included all participants who had at least 1 postdose zanubrutinib plasma concentration
- reporting Status
- POSTED
- time Frame
- Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)
- title
- Elimination Half Life (t1/2)
- type
- SECONDARY
- unit Of Measure
- Hours
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice